Transgenlc mouse assays have provided an unprecedented opportunity to study mutagenesis in diverse rodent tissues. In this article data from Muta™Mouse mutagenicity assays based on the Escherichia coli gene lacZ were analyzed systematically using liver and bone marrow as potential target tissues. Sources of variation, including plates (within packaging reactions), packaging reactions (within animals) and animals, were evaluated for extrabinomial variation. Although hardly any evidence of overdispersion was detected at the plate level, limited evidence of extra-binomial variation was observed at the packaging reaction level. There was, however, much stronger evidence of overdispersion at the animal level. Statistical tests for increasing trend in mutant frequency with increasing dose were also performed at the annual level. A significant increasing trend following exposure to JV-nitrosodibenzylamine was detected in liver but not in bone marrow. A logistical model was used to further describe the dose-response relationship observed in Nnitrosodibenzylamine-treated liver tissue.
Introduction
Transgenic mouse assays are now used widely in the study of mutagenesis in diverse rodent tissues and to test chemicals for genotoxic potential. Currently two transgenic mouse models are available commercially for mutation studies in vivo: Big Blue™ (Kohler et al, 1991) , which carries the loci gene, and Muta™Mouse (Gossen et al., 1989) , which carries the lacZ gene. Statistical issues such as the sources of variation, sample size, tests for treatment effects and modeling of dose-response relationships have been investigated for the Big Blue™ loci gene (Carr and Gorelick, 1994, 1995; Piegorsch et al., 1994 Piegorsch et al., , 1995 Fung et al., 1997) . Sources of variability in Muta™Mouse data in male germ cells from five different laboratories were reported by Piegorsch et al. (1997) . In this paper we will concentrate on the Muta™Mouse (strain 40.6), using results from the liver and bone marrow as potential target tissues. In addition to examining sources of variability in mutant frequency data, we tested for trend in mutant frequencies with increasing exposure to Af-nitrosodibenzylamine (NDBzA), and modeled the corresponding dose-response relationship.
Materials and methods
The transgenic Muta™Mouse strain 40.6 used in this study is described in detail by Gossen et aL (1989) . The transgenic shuttle vector contains a complete bacterial lacZ gene that can be recovered from the mouse DNA and analyzed for mutations. Mice carrying single copies of the transgene were bred previously to be disomic for use in mutagenicity studies (Gossen et aL, 1989) .
Details of the experimental procedures involving DNA isolation, recovery of X phage and positive selection of lacZ mutants (Gossen et aL, 1992) can be found in Vijg and Douglas (1996) and Douglas et al. (1995a,b) . Very briefly, DNA was isolated from defrosted previously frozen tissues, packaged into bacteriophage X and adsorbed to Escherichia coli C (AlacZ~, galE~). To estimate mutant frequency the bacteriophage/cell suspension resulting from each packaging reaction was distributed over four 9 cm Petri plates containing phenyl p-D-galactoside (P-gal; Sigma), which permits only lacZ mutants to form plaques. To estimate total cells added to the mutant selection plates above, the bacteriophage/cell suspension was diluted 134X with unadsorbed cells and distributed over four plates. Two opposing 1/8 sectors were scored on each of these plates and the total was multiplied by four and adjusted for the dilution factor to estimate the total number of cells plated on each selection plate. Titer plates containing <100 plaques were not scored.
To study variability of spontaneous mutant frequencies in liver and bone marrow 10 untreated male animals were randomly selected. DNA from the liver or bone marrow of all 10 animals was packaged on each of three different days. For each animal-packaging reaction combination four plates were cultured for analysis of plaques. To study variability in a dose-response experiment animal* were treated (p.o.) with NDBzA once and killed after 90 days. The doses selected were 0, 100, 425 and 750 mg/kg, with five male animals per dose. For each animal three packaging reactions were employed and one of these three reactions was used with all animals on the same day. In other words, DNA from the liver or bone marrow of all animals in the experiment was packaged on each of three separate days. This is a form of 'blocking', as described in Piegorsch et aL (1995) . If there is some unknown factor affecting the mutant frequencies on a given day it will do so for all the dose groups. This type of design helps prevent biases due to such factors, thereby permitting valid comparisons between doses. An equal number of replicates were used at each level of the experimental design, including the number of animals within each dose group, the number of packaging reactions for each animal and the number of plates for each packaging reaction. Separately derived mutation data, which were not collected in such a systematic design, have been published previously (Douglas etaL, 1994; Jiaoef aL, 1997 ).
Due to their common origin, the mutant frequency (MF) in tissues from the same animal are likely to be positively correlated, inducing extra variation relative to the common binomial distribution. Consequently, the presence of overdispersion in mutant frequencies must be examined and taken into account in analyses of data from transgenic mouse experiments.
To establish the notation used in this paper let x, jk and n^ be the number of mutant plaques and total plaques respectively in the Wi plate of the yth package of the ith animal, (i = 1,..., /, j = 1,..., mj. Let J^J = IfrXyi, ty = Xt"ijk .The mutant frequency is defined as the ratio of the confirmed mutant plaques to the number of plaque forming units (p.f.u.), i.e. MF = x\^n^. We also denote x\ = Lpty, «j = 2^n,j, x = J+X|, n = lyij and M «= 1^.
Results

Sources of variability
To identify the sources of variability in the mutant frequency data we followed the step-up procedure of Piegorsch et al. (1994) . First, Cochran's binomial variance test (Cochran, 1954) was used to check for extra-binomial variation at the plate level within a packaging reaction for a given animal. The test statistic is 'To whom correspondence should be addressed. Tel: +1 519 253 4232; Fax: +1 519 971 3649; Email: kfung@uwindsor.ca is the pooled mutant frequency. In the absence of overdispersion the distribution of XB 2 ' S approximately y} with n tJ -I degrees of freedom. We rejected the null hypothesis that the observations are binomially distributed when the test statistic was large or, conversely, when the corresponding P value was small.
If there was no strong evidence of extra-binomial variation among plates within packaging reactions the plate mutant frequencies were aggregated to the packaging reaction level and tested again. If no excess packaging reaction to packaging reaction variability was found within an animal aggregation continued up to the animal level. Since many of these tests were performed, the overall type I error will be larger than the level we set for each test. Consequently, we elected not to declare excess variability significant unless the P value for each test was<0.01.
For the spontaneous mutation data from both bone marrow and liver (Tables I and II) there were no cases where the test statistic was significant at the 1% level at the plate level within a package, providing no evidence of extra-binomial variation at the plate level. We then summed across replicate plates in the same packaging reaction for each animal to obtain a pooled estimate of mutant frequency (MF). A similar analysis of these pooled MFs also confirmed no evidence of extra-binomial variation in both bone marrow and liver. When we further aggregated the mutant frequencies to the animal level we found significant overdispersion (P < 0.001) in bone marrow, but not in liver (P = 0.57).
For the dose-response data in liver (Table III) there was no excess variation at the plate level within packaging reactions nor at the packaging reaction level within animals at the 1% level of significance. At the animal level the highest two doses (425 and 750 mg/kg) exhibited extra-binomial variation, whereas the control group and 100 mg/kg dose group did not. For the NDBzA data in bone marrow (Table IV) two cases showed excess binomial variation at the plate level and one at the packaging reaction level. When the data were aggregated to the animal level the data showed some evidence of overdispersion in all four dose groups.
These results concur with previous studies using the lacl gene (e.g. CarrandGorelick, 1994; Piegorsch era/., 1994 Piegorsch era/., ,1995 Fung et al., 1997) and the lacZ gene in germ cells (Piegorsch et al., 1997) , indicating that excess plate to plate variability is not of major concern. Excess variability may occasionally arise at the packaging reaction level and is an important factor at the animal level. Furthermore, we found more variability in bone marrow than in liver.
Tests for trend
In the NDBzA dose-response experiment formal tests of trend were applied to the animal level MFs in liver and bone marrow to determine if there was a significant increasing trend with increasing dose of NDBzA. Fung et al. (1994 Fung et al. ( ,1997 investigated several tests for trend for correlated binary data and found that some quasi-likelihood score tests perform well even for small sample sizes. Two such score tests are discussed below.
Quasi-likelihood score tests for trend were proposed by Lefkopoulou et al. (1989) and Ryan (1993) for overdispersed binomial data. This class of tests is particularly flexible in that 1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3   21  21  14  11  13  14  12  19  12  8  29  14  17  3  13  11  8  18  13  16  21  29  17  16  16  15  19  11  12  5   254 464  236 572  154 401  281 633  286 it requires specification only of the mean and variance functions of the data. The score statistic given by Lefkopoulou et al. (1989) is of the form i'
where <? = X Z "u Ji/ Z X "«• Vi = Z (Xi J ~ n 'i^2 and ' i > J J p 0 = x/n. This test is also referred to as the generalized Cochran-Armitage test statistic by Carr and Gorelick (1994, 1995) . Ryan (1993) also considers the modified statistic
where p = [(M -1)-'X Z' (j: iJ ~ "u A>) 2 /«ij/>o(l -p 0 ). The distribution of both test statistics (7/LMR, TR) is approximately standard normal, provided that the number of experimental units in each dose is large. Results are presented in Table V for liver and bone marrow using animals as experimental units. Without loss of generality we may scale the doses so that the highest dose is equal to 1 (i.e. d x = 0, d 2 = 0.133, d 3 = 0.567, d 4 = 1) For the liver doseresponse data we found that both statistics indicate a highly significant increasing trend in MF with respect to dose. For the bone marrow dose-response experiment, on the other hand, both me ?LMR and T R statistics are not significant when animals are used as the experimental unit. We conclude that the effect of NDBzA is more significant in liver than in bone marrow.
Dose-response modeling
Once a significant trend in MF is identified it is often of interest to describe the dose-response relationship in more detail. We fitted the logistical model 1 1 + exp (-a -fW) to the mutant frequency data in NDBzA-treated liver using animals as experimental units and scaled doses d\ = (0, 0.133, 0.567, 1.0). [Here p(d) denotes the probability of mutation at dose d.] Figure 1 shows a plot of liver MFs with respect to NDBzA dose when data were aggregated to the animal level.
Estimates of the logistical model parameters a and p were obtained by solving the estimating equations given in Appendix A. The estimating equation approach avoids making full parametric assumptions about the overdispersed binomial data (MF); instead, only the mean and variance structure are assumed. This leads to mathematically tractable consistent estimates of the parameters. To protect against misspecification of the variance of the data the empirical adjustments of Liang and Zeger (1986) were then used to derive robust estimates of the asymptotic variance and covariance of the estimates. Detailed formulae are given in Appendix A.
Results are given in Table VI showing estimates of the parameters of the logistical dose-response models fitted to animalbased MFs in NDBzA-treated liver. A graphical representation of the fitted model is given in Figure 1 . 66  66  66  67  67  67  68  68  68  69  69  69  70  70  70  76  76  76  77  77  77  78  78  78  79  79  79  80  80  80  81  81  81  82  82  82  83  83  83  84  84  84  85  85  85  86  86  86  87  87  87  88  88  88  89  89  89  90  90  90   1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3  1  2  3   12  18  12  16  21  21  17  37  22  7  12  2  10  17  7  18  26  10  4  9  3  19  21  32  25  18  15  10  11  2  42  50  31  25  39  20  17  17  33  21  23  19  54  65  64  41  42  30  23  42  18  23  64  26  37  58  18  22  44  37   159 703  237 898  223 319  171631  273 019  231 In this paper we have described statistical analyses of lacZ MF data from Muta™Mouse mutagenicity assays of liver and bone marrow. We employed random assignment of animals to each dose, equal replication to achieve a balanced experimental design and blocking to prevent biases due to unadjusted daily packaging 252 reaction factors. Generalized score tests for trend were applied to the mutant frequencies in liver and bone marrow to determine if there was a significant increase in trend with increasing dose ofNDBzA.
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The statistical techniques used both for testing for trend and modeling dose-response are intended specifically for use with overdispersed binomial data of the type generated in the trans-genic mouse assay. Extra-binomial variation in tfiis assay arises as a consequence of correlation among observations of mutant frequency in the same animal. The statistical methods used in dose-response modeling are robust in the sense, that it is not necessary to fully specify the distribution of the data; rather, specification of only the mean and variance structure of the data is required to apply the techniques used here. Such modeling Table V . Test statistics for increasing trend in animal level mutant frequency with dose (P values in parentheses)
Liver
Bone marrow dependent, determined by processes such as rate of cell turnover, metabolism and the capacity to repair endogenous DNA damage (see for example Carrand Gorelick, 1994; Douglas etal., 1996; Fung et al., 1997;  for additional results in skin liver and bladder). methods have been used previously to describe dose-response relationships observed in mutant frequency data derived from the lacl transgenic mouse assay (Fung et al., 1997) . As found previously with data from the lad gene in liver and bladder and the lacZ gene in germ cells, little evidence of extrabinomial variation was found among replicate plates within packages. Limited evidence of overdispersion was found at the packaging reaction level and much stronger evidence at the animal level. This suggests that artifacts arising from technicalities of the work-up or packaging/plating procedures are not an important source of variability in this assay. On the other hand, animal to animal variation in mutant frequency, which reflects individual responses, is an important biological source of variation. Furthermore, we found more variability in bone marrow than in liver at the animal level. Mutant frequencies in liver increased following increasing doses of NDBzA. but not in bone marrow. These observations indicate that NDBzA MFs are tissue
